Biological Activity and Antidiabetic Potential of C-Terminal Octapeptide Fragments of the Gut-Derived Hormone Xenin
Open Access
- 31 March 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (3) , e0152818
Abstract
Xenin is a peptide that is co-secreted with the incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), from intestinal K-cells in response to feeding. Studies demonstrate that xenin has appetite suppressive effects and modulates glucose-induced insulin secretion. The present study was undertaken to determine the bioactivity and antidiabetic properties of two C-terminal fragment xenin peptides, namely xenin 18–25 and xenin 18–25 Gln. In BRIN-BD11 cells, both xenin fragment peptides concentration-dependently stimulated insulin secretion, with similar efficacy as the parent peptide. Neither fragment peptide had any effect on acute feeding behaviour at elevated doses of 500 nmol/kg bw. When administered together with glucose to normal mice at 25 nmol/kg bw, the overall insulin secretory effect was significantly enhanced in both xenin 18–25 and xenin 18–25 Gln treated mice, with better moderation of blood glucose levels. Twice daily administration of xenin 18–25 or xenin 18–25 Gln for 21 days in high fat fed mice did not affect energy intake, body weight, circulating blood glucose or body fat stores. However, circulating plasma insulin concentrations had a tendency to be elevated, particularly in xenin 18–25 Gln mice. Both treatment regimens significantly improved insulin sensitivity by the end of the treatment period. In addition, sustained treatment with xenin 18–25 Gln significantly reduced the overall glycaemic excursion and augmented the insulinotropic response to an exogenous glucose challenge on day 21. In harmony with this, GIP-mediated glucose-lowering and insulin-releasing effects were substantially improved by twice daily xenin 18–25 Gln treatment. Overall, these data provide evidence that C-terminal octapeptide fragments of xenin, such as xenin 18–25 Gln, have potential therapeutic utility for type 2 diabetes.Keywords
This publication has 30 references indexed in Scilit:
- Degradation, insulin secretion, glucose-lowering and GIP additive actions of a palmitate-derivatised analogue of xenin-25Biochemical Pharmacology, 2012
- Loss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 DiabetesDiabetes Care, 2011
- Xenin-25 Potentiates Glucose-dependent Insulinotropic Polypeptide Action via a Novel Cholinergic Relay MechanismJournal of Biological Chemistry, 2010
- Reversal of islet GIP receptor down-regulation and resistance to GIP by reducing hyperglycemia in the Zucker ratBiochemical and Biophysical Research Communications, 2007
- Xenin reduces feed intake by activating the ventromedial hypothalamus and influences gastrointestinal transit rate in chicksBehavioural Brain Research, 2007
- Xenin - A ReviewPeptides, 1998
- Identification of proxenin as a precursor of the peptide xenin with sequence homology to yeast and mammalian coat protein αPeptides, 1996
- Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.Journal of Clinical Investigation, 1993
- Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.Journal of Clinical Investigation, 1984
- Development of Glucose Intolerance and Impaired Plasma Insulin Response to Glucose in Obese Hyperglycaemic (ob/ob) MiceHormone and Metabolic Research, 1981